Peptide therapy TikTok claims: what the research actually supports

What did @dustin_h04 actually say?

The creator walked through a basic reconstitution protocol for MOTS-c, a mitochondrial-derived peptide. Starting with a 10 mg vial and 1 mL of bacteriostatic water, they calculated a concentration of 100 units per mL. Their suggested starting point: "1.5 mg twice a week," pulling 15 units per dose. After two weeks, they suggested scaling to "anywhere between 5 to 10 mgs a week, taking in two or three doses." That is essentially the entire video. No context about what MOTS-c is, what it does, or why someone might use it. Just math and a schedule.

To be fair, the reconstitution arithmetic is correct. One mL into a 10 mg vial does give you 1 mg per 10 units, so 15 units equals 1.5 mg. That part checks out.

Does the science back this up?

Here is the uncomfortable truth: there is almost no human clinical data on MOTS-c dosing. The dosing ranges cited in this video are not derived from peer-reviewed human trials because those trials barely exist yet.

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome. Early research, primarily in mice, showed it could improve insulin sensitivity and reduce diet-induced obesity (Lee et al., 2015, Cell Metabolism). A follow-up study found MOTS-c levels decline with age and that exogenous administration improved physical performance in older mice (Lu et al., 2019, Nature Communications). Human observational data is limited to studies showing circulating MOTS-c levels correlate with metabolic health markers (Kim et al., 2018, Aging Cell).

None of those studies establish a validated human dosing protocol. The "1.5 mg twice a week" starting dose circulating in peptide communities appears to originate from anecdotal self-experimentation and forum consensus, not controlled trials. That does not make it definitively wrong. It just means nobody has actually tested it rigorously in humans.

What did they get wrong (or right)?

The math is right. The reconstitution instructions are accurate, and explaining unit-to-milligram conversion is genuinely useful for harm reduction. Credit where it is due.

What is missing is everything else. The creator presents a dosing ramp-up, "5 to 10 mgs a week" after the first two weeks, with no mention that this range has no clinical validation in humans. Presenting it as a straightforward guide implies a level of established evidence that simply does not exist.

There is also no mention of administration route. MOTS-c is typically discussed in the context of subcutaneous injection, which carries real considerations around sterility, injection site reactions, and sourcing. A 30-second video that tells you how many units to pull but not how to safely administer the compound is incomplete in a way that matters.

• Reconstitution math: accurate
• Dosing ranges sourced from human trials: no supporting evidence
• Safety or administration context: entirely absent
• Any discussion of what MOTS-c actually does: absent

What should you actually know?

MOTS-c is a genuinely interesting area of research. The mitochondrial connection to aging and metabolic regulation is real science, and researchers like Changhan David Lee at USC have built a credible body of work here. But interesting early research is not the same as a validated therapeutic protocol.

The peptide is not FDA-approved. It is not available through standard pharmacies. Anything being used right now is either compounded or sourced from research chemical suppliers, and quality control across those sources varies considerably. That context matters when someone is deciding whether to inject something based on a 30-second TikTok.

If you are interested in peptide therapies, the appropriate path runs through a licensed clinician who can review your bloodwork, assess your actual metabolic status, and discuss whether emerging compounds like MOTS-c make sense for you. Dosing guides built from community consensus and posted without clinical context are a starting point for a conversation, not a prescription.

The bottom line

The video is not reckless, but it is thin. Accurate unit math wrapped around dosing claims that have no human trial basis, delivered with zero safety context, is the kind of content that feels informative while leaving out most of what you need to make a real decision. MOTS-c research is worth watching. This video is not the place to learn about it.